Myasthenia gravis (MG) care is evolving rapidly, driven by innovative treatments and a growing recognition of the condition’s impact beyond muscle weakness. While new therapies are improving outcomes and shifting care towards a more patient-centred approach, challenges such as delayed diagnosis, unequal access to specialist care, and the under-recognition of fatigue and mental health issues remain. Drawing on insights from leading clinicians, health economists, and patient advocates across Europe, this article explores how MG management is changing and what is needed to deliver more equitable, holistic care.
